Published in Wien Klin Wochenschr on September 17, 2013
Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China. Medicine (Baltimore) (2016) 0.77
Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria. BMC Public Health (2016) 0.75
Human papillomavirus genotypes associated with cervical precancerous lesions and cancer in the highest area of cervical cancer mortality, Longnan, China. Infect Agent Cancer (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med (1998) 20.81
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med (2007) 15.40
Human papillomavirus and cervical cancer. Lancet (2007) 12.47
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer (2007) 10.29
Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol (2008) 6.20
Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet (2006) 5.65
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
The epidemiology of human papillomavirus infections. J Clin Virol (2005) 3.63
Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ (2008) 3.45
Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol (2006) 3.34
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis (2012) 3.25
After conisation of the cervix, the perinatal mortality as a result of preterm delivery increases in subsequent pregnancy. BJOG (2009) 2.34
Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev (2005) 2.24
Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol (2002) 1.94
Reducing the burden of glandular carcinomas of the uterine cervix. Am J Obstet Gynecol (2007) 1.82
CK17 and p16 expression patterns distinguish (atypical) immature squamous metaplasia from high-grade cervical intraepithelial neoplasia (CIN III). Histopathology (2007) 1.68
Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer (2012) 1.48
The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials. Int J Cancer (2011) 1.31
Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine (2012) 1.08
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. Int J Cancer (2011) 0.95
Obstetric and neonatal outcome after surgical treatment of cervical dysplasia. Eur J Obstet Gynecol Reprod Biol (2012) 0.86
Why do human papillomavirus infections induce sharply demarcated lesions of the cervix? J Low Genit Tract Dis (2008) 0.75
Multifocal stromal invasion in microinvasive squamous cell carcinoma of the cervix: how to measure and stage these lesions. Int J Gynecol Pathol (2002) 0.75
Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial. Wien Klin Wochenschr (2008) 0.75
Microinvasive carcinoma of the cervix: site of first focus of invasion. Obstet Gynecol (2001) 0.75
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis (2009) 2.92
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev (2011) 1.74
Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg (2004) 1.72
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. Int J Cancer (2003) 1.50
Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer (2012) 1.48
Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev (2010) 1.34
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer (2009) 1.33
Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin Cancer Res (2003) 1.32
The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials. Int J Cancer (2011) 1.31
Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res (2003) 1.30
VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery (2006) 1.24
Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated with poor outcome in node-negative breast cancer. Anticancer Res (2007) 1.22
Human papillomavirus infections and vulvar disease development. Cancer Epidemiol Biomarkers Prev (2009) 1.15
Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res Treat (2006) 1.14
Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res (2005) 1.13
Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int J Cancer (2011) 1.12
Etiology of vulvar cancer will impact on treatment options and therapy outcome: Two major pathways of vulvar cancer. Gynecol Oncol (2013) 1.10
Lymphatic vessels and lymphangiogenesis in female cancer: mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies (Review). Oncol Rep (2002) 1.07
HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer. Breast Cancer Res Treat (2013) 1.00
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. Int J Cancer (2011) 0.95
Development of epithelial and mesenchymal regionalization of the human fetal utero-vaginal anlagen. J Anat (2013) 0.95
Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer (2010) 0.93
Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women. J Adolesc Health (2012) 0.91
Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer. Mol Cancer Ther (2010) 0.91
Intumescent cataract after topical mitomycin-C for conjunctival malignant melanoma. Am J Ophthalmol (2003) 0.90
Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Mol Immunol (2012) 0.89
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium. BMC Cancer (2013) 0.89
Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium. Mol Cancer (2012) 0.88
Should lymphadenectomy be performed in patients with endometrial stromal sarcoma? Gynecol Oncol (2005) 0.88
Expression of BRAF V600E mutant protein in epithelial ovarian tumors. Appl Immunohistochem Mol Morphol (2013) 0.87
Immunization with mimotopes prevents growth of carcinoembryonic antigen positive tumors in BALB/c mice. Clin Cancer Res (2007) 0.87
Parametrial spread of cervical cancer in patients with negative pelvic lymph nodes. Gynecol Oncol (2002) 0.86
Towards the expression of sex hormone receptors in the human vocal fold. J Voice (2006) 0.86
Expression of indoleamine 2,3-dioxygenase in carcinoma of human endometrium and uterine cervix. Adv Exp Med Biol (2003) 0.86
Human papilloma virus infection prior to coitarche. Am J Obstet Gynecol (2009) 0.85
Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin Cancer Res (2005) 0.85
High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting. Int J Cancer (2014) 0.84
Delivery outcome after cold-knife conization of the uterine cervix. Gynecol Oncol (2006) 0.84
The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer. BMC Cancer (2013) 0.84
Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. Int J Cancer (2014) 0.84
RPE65 of retinal pigment epithelium, a putative receptor molecule for plasma retinol-binding protein, is expressed in human keratinocytes. J Invest Dermatol (2004) 0.84
Microsatellite polymorphism in the heme oxygenase-1 gene promoter and cardiac allograft vasculopathy. J Heart Lung Transplant (2005) 0.84
hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer. Clin Cancer Res (2011) 0.84
Hermann Lebert (1813-1878): a pioneer of diagnostic pathology. Virchows Arch (2009) 0.83
The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential. Gynecol Oncol (2010) 0.83
The prognostic role of human papillomavirus in patients with vaginal cancer. Int J Gynecol Cancer (2011) 0.82
Kaposi's sarcoma of the conjunctiva leads to a diagnosis of acquired immunodeficiency syndrome. Acta Ophthalmol Scand (2003) 0.82
The accuracy of intraoperative frozen section of the inguinal sentinel lymph node in vulvar cancer. Anticancer Res (2009) 0.82
Expression of FcRn, the MHC class I-related receptor for IgG, in human keratinocytes. J Invest Dermatol (2005) 0.82
Thrombocytosis and anaemia in women with recurrent ovarian cancer prior to a second-line chemotherapy. Anticancer Res (2003) 0.82
HPV-type distribution and reproducibility of histological diagnosis in cervical neoplasia in Poland. Pathol Oncol Res (2014) 0.81
ABC transporter gene expression in benign and malignant ovarian tissue. Gynecol Oncol (2009) 0.81
Lymphatic spread of endometriosis to pelvic sentinel lymph nodes: a prospective clinical study. Fertil Steril (2011) 0.81
Elevated serum concentrations of androgens in women with pregnancy-induced hypertension. Wien Klin Wochenschr (2003) 0.81
Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium. Mol Cancer (2014) 0.80
Impact of lifestyle factors on preneoplastic changes in prophylactic oophorectomies of BRCA mutation carriers. Eur J Cancer Prev (2012) 0.80
KRAS mutation analysis in genomic DNA isolated from formalin-fixed paraffin-embedded ovarian tissue: evaluation of a strip-based reverse-hybridisation assay. J Clin Pathol (2011) 0.80
BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-beta treatment. Gynecol Oncol (2010) 0.79
Conization of the uterine cervix: does the level of gynecologist's training predict margin status? Int J Gynecol Pathol (2012) 0.79
Short-term antibiotic treatment of pelvic actinomycosis. Int J Gynaecol Obstet (2007) 0.79
Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. Anticancer Res (2004) 0.79
Gene expression signatures of breast tissue before and after cross-sex hormone therapy in female-to-male transsexuals. Fertil Steril (2010) 0.78
FcgammaRIII expression on cultured human keratinocytes and upregulation by interferon-gamma. J Invest Dermatol (2002) 0.78
Monoclonal gamma-T-cell receptor rearrangement in vulvar lichen sclerosus and squamous cell carcinomas. Am J Pathol (2002) 0.78
An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age. Pediatr Infect Dis J (2015) 0.78
Estrogen replacement therapy and tamoxifen are contraindicated in patients with endometrial stromal sarcoma. Gynecol Oncol (2006) 0.78
A randomized trial of vaginal prostaglandin E2 for induction of labor. Insert vs. tablet. J Reprod Med (2002) 0.78
The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status. J Cancer Res Clin Oncol (2005) 0.77
Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Hum Vaccin Immunother (2015) 0.77
Immunohistochemical examinations of sex hormone receptors in benign vocal fold lesions. Folia Phoniatr Logop (2009) 0.77
Spread of endometriosis to pelvic sentinel lymph nodes: gene expression analysis. Eur J Obstet Gynecol Reprod Biol (2013) 0.76
Serum levels of squamous cell carcinoma antigen as a predictor of inguinofemoral lymph node metastasis in patients with vulvar cancer. J Reprod Med (2002) 0.76
Relaxin and gonadal steroid receptors in uterosacral ligaments of women with and without pelvic organ prolapse. Int Urogynecol J (2011) 0.76
The lack of laminin-5 as a prognostic marker in low-grade cervical squamous intraepithelial lesions: correlation with clinical follow-up data. Int J Gynecol Pathol (2007) 0.75
Cervical cancers after human papillomavirus vaccination. Obstet Gynecol (2009) 0.75
The impact of a single- or double-layer closure on uterine rupture. Am J Obstet Gynecol (2003) 0.75
Is tamoxifen an option for patients with endometrial stromal sarcoma? Gynecol Oncol (2005) 0.75
Initial diagnosis of CIN 2-should patients be managed expectatively? Am J Obstet Gynecol (2011) 0.75
Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer. Int J Gynecol Pathol (2013) 0.75
Hormonal treatment with aromatase inhibitors for patients with endometrial stromal sarcoma. Gynecol Oncol (2005) 0.75
What do women with gynecologic cancer know about HPV and their individual disease? A pilot study. BMC Cancer (2014) 0.75
Should patients with cytologic high-grade intraepithelial lesions of the cervix be treated without colposcopic-guided biopsy? Am J Obstet Gynecol (2011) 0.75
Lymph node metastasis in FIGO stage IA1 cervical cancer? Gynecol Oncol (2005) 0.75
Grading of malignancy has no clinical relevance in patients with endometrial stromal sarcoma. Gynecol Oncol (2007) 0.75
Do drugs that stimulate ovulation increase the risk for endometrial stromal sarcoma? Hum Reprod (2005) 0.75
Heterogeneous gonadotropin-releasing hormone receptor expression in ovarian granulosa cell tumors. Gynecol Oncol (2006) 0.75
Groin metastasis after extensive microinvasive vulvar cancer. A case report. J Reprod Med (2007) 0.75
Anogenital Human Papillomavirus Prevalence is Unaffected by Therapeutic Tumour Necrosis Factor-alpha Inhibition. Acta Derm Venereol (2016) 0.75
Cytologic diagnosis of low grade endometrial stromal sarcoma by staining for estrogen and progesterone receptors. Acta Cytol (2002) 0.75